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 Management of TB/HIV co-infected patients in Eastern Europe (EE) is suboptimal 59 
 TB/HIV co-infected patients diagnosed with MDR-TB received inferior TB treatment 60 
with limited numbers of active drugs 61 
 Access to rapid diagnostics for TB is urgently needed 62 
 Performance of extended DST for all patients diagnosed with MDR-TB is required 63 
 Integration of TB and HIV clinics can potentially ensure better management of patients 64 
in EE 65 
Abstract 66 
Objectives 67 
Mortality among HIV patients with tuberculosis (TB) remains high in Eastern Europe (EE), but details of TB 68 
and HIV management remain scarce.  69 
Methods 70 
In this prospective study, we describe the TB treatment regimens of patients with multi-drug resistant 71 
(MDR) TB and use of antiretroviral therapy (ART).  72 
Results 73 
A total of 105 HIV-positive patients had MDR-TB (including 33 with extensive drug resistance) and 130 pan-74 
susceptible TB. Adequate initial TB treatment was provided for 8% of patients with MDR-TB compared with 75 
80% of those with pan-susceptible TB. By twelve months, an estimated 57.3% (95%CI 41.5-74.1) of MDR-TB 76 
patients had started adequate treatment. While 67% received ART, HIV-RNA suppression was 77 
demonstrated in only 23%. 78 
Conclusions 79 
Our results show that internationally recommended MDR-TB treatment regimens were infrequently used 80 
and that ART use and viral suppression was well below the target of 90%, reflecting the challenging patient 81 
population and the environment in which health care is provided. Urgent improvement of management of 82 
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patients with TB/HIV in EE, in particular for those with MDR-TB, is needed and includes widespread access 83 
to rapid TB diagnostics, better access to and use of second-line TB drugs, timely ART initiation with viral 84 
load monitoring, and integration of TB/HIV care.   85 
 86 
Introduction 87 
Although rates of tuberculosis (TB) have begun to decline in recent years, simultaneous rapid increases in 88 
the relative contribution of multi-drug resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB) are 89 
worrying (1-4). Eastern Europe (EE), together with central Asia, has the worlds’ highest proportions of MDR- 90 
and XDR-TB with 9-35% of new TB cases and 49-77% of re-treatment cases being diagnosed with MDR-TB in 91 
Belarus, Russia and Ukraine compared with 1-3% of new cases and 4-14% of re-treatment cases in Italy, 92 
Switzerland and the United Kingdom (1, 5-8). 93 
The MDR-TB epidemic in EE is further complicated by high rates of HIV co-infection. Whereas most other 94 
regions have reported declining rates of new HIV infections over recent years, EE has experienced an 95 
increase of 30% in annual number of new HIV infections since the turn of the millennium (9, 10). The 96 
TB/HIV epidemic in EE is primarily driven by injection drug users (IDU) who often access health care late, 97 
are co-infected with hepatitis C (HCV), and frequently have poor treatment compliance and retention in 98 
care (11-14). We recently reported a one-year mortality rate of 27% for TB/HIV co-infected patients in EE, 99 
and patients diagnosed with MDR-TB had roughly three-times higher mortality compared to those with 100 
drug-susceptible TB. Further, patients from EE who initiated TB treatment with three or more active drugs 101 
had significantly lower risk of death compared to patients who received less than three active TB drugs 102 
(13% vs 34%) (15). 103 
Treatment for MDR-TB is complex in terms of pill burden, drug-interactions and toxicity, and costly (1, 16-104 
18). MDR-TB therapy  is prolonged (typically at least 20 months) although the 2016 WHO guidelines include 105 
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an option for shorter MDR-TB regimens in specific cases (16, 19). Preliminary results with a novel six 106 
months regimen (consisting of pretomanid, bedaquiline and linezolid) may be highly effective to treat MDR-107 
TB (20). For now, standard of care consists of at least five drugs including a fluoroquinolone, a second-line 108 
injectable, at least two other active drugs plus pyrazinamide during the intensive phase of treatment (19). 109 
Reported MDR-TB treatment success rates, however, have been generally low, in particular for HIV-positive 110 
individuals, and rarely exceed 50% (18, 21). 111 
Epidemiological data and detailed descriptions of the clinical management of HIV-positive patients with 112 
MDR-TB in EE remain relatively scarce (22). We prospectively studied patients with TB/HIV co-infection in 113 
EE and in this paper report on the management of those with MDR-TB.   114 
 115 
Methods 116 
Study design and participants 117 
The TB:HIV Study is a prospective cohort study including 62 TB and HIV clinics in 19 countries in EE, Western 118 
Europe, Southern Europe, and Latin America. Adult (>16 years) HIV-positive patients with a TB diagnosis 119 
were consecutively enrolled between 01/01/2011 and 31/12/2013. Demographic, clinical, and laboratory 120 
data were collected on standardized case report forms at baseline and month 6, 12, and 24 (12); further 121 
details are available at http://www.cphiv.dk/TBHIV. All participating clinics obtained ethical approval in 122 
accordance with local rules and legislations, and the study was performed in accordance with the strobe 123 
guidelines for observational studies (23). 124 
Study definitions 125 
Patients from EE were included in the present analyses if they had definite or probable TB. A diagnosis of 126 
definite TB was based on positive culture or molecular diagnostics for Mycobacterium tuberculosis (Mtb), 127 
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and probable TB on the presence of acid fast bacilli and/or granulomatous inflammation on sputum smear 128 
or tissue biopsy specimens (12). Baseline was defined as the date TB treatment was initiated, and a 129 
baseline culture was defined as a culture obtained within one month of baseline. All TB drugs initiated 130 
within 10 days of baseline were considered to constitute initial TB treatment. Standard definitions of MDR-131 
TB, pre-XDR-TB, and XDR-TB were used (see box), and pan-susceptible TB was defined as TB without 132 
documented drug resistance. TB treatment regimens were categorized in line with general 133 
recommendations (16, 24): 1: Treatment regimens containing RHZ (with or without ES) targeting drug-134 
susceptible TB (24), 2: Treatment regimens containing RHZ plus a fluoroquinolone AND a second line 135 
injectable, providing empiric cover for both susceptible TB and MDR-TB, 3: Five or more MDR-TB drugs 136 
(including a fluoroquinolone AND a second line injectable) providing appropriate empiric cover for MDR-TB, 137 
4: Regimens containing a fluoroquinolone OR a second line injectable (but not both), providing inadequate 138 
cover for MDR-TB , and 5: Any other drug combination (Fig. 1). For patients with MDR-TB, the number of 139 
active drugs in the TB regimen was calculated at various time points based on the susceptibility pattern of 140 
isolates obtained up to the given time point. If a Drug Susceptibility Test (DST) result was not available for a 141 
specific drug included in the regimen, the given Mtb isolate was either considered potentially susceptible to 142 
this drug (potentially active drugs) or resistant to this drug (known active drugs), thus representing a “best 143 
case” and “worst case” treatment scenario.  144 
Antiretroviral treatment (ART) was defined as a combination of >3 antiretroviral drugs from any ART class. 145 
Participants were considered lost to follow-up (LTFU) when no attendance was recorded at the relevant 146 
time points in those who were not known to have died. 147 
Statistical analysis 148 
Descriptive statistics were used for baseline characteristics of patients. Patients were stratified into three 149 
groups: MDR-TB at baseline, pan-susceptible TB at baseline, and other (no baseline DST results available or 150 
the presence of non-MDR-TB resistance patterns). MDR-TB patients who had extended DST available were 151 
Page 6 of 28
7 
 
further classified as having pre-XDR or XDR-TB. Baseline characteristics among patients who had MDR-TB, 152 
those who were fully susceptible and those who did not have any baseline DST available were compared 153 
using the chi-squared test or Fisher’s exact test as appropriate for categorical variables, whereas the 154 
Kruskal-Wallis test was used to compare continuous variables. 155 
TB and HIV treatment regimens were analyzed at months 0, 3, 7, 13, and 21. Kaplan-Meier estimates were 156 
used to estimate time to receiving adequate treatment for MDR-TB (category 3: five or more MDR-TB drugs 157 
including a fluoroquinolone AND a second line injectable), and time to starting ART censoring at last visit 158 
date (maximum 21 months) or death, whichever occurred first. Further, Kaplan-Meier estimates were also 159 
used to estimate the time to starting ART. All statistical analyses were performed using SAS (Statistical 160 
Analysis Software, Cary, NC, USA, version 9.3).  161 
 162 
Results 163 
Patient characteristics 164 
Of 1406 patients enrolled into the TB:HIV study, 834 received care in EE, of these 485 had definite or 165 
probable TB and were included in this analysis (supplementary Fig. 1). A positive culture for Mtb was 166 
reported in 383 (79%) patients, 302 (79%) of these were tested for resistance to any drug, 270 (70%) for 167 
both R and H, and 68 (18%) for fluoroquinolone or second line injectables. Of the 485 patients, 105 (22%) 168 
had MDR-TB, 130 (27%) had pan-susceptible TB at baseline and 183 (38%) had no DST results; the 169 
remaining 67 (14%) had non-MDR-TB resistance patterns and were excluded from subsequent analyses. 170 
Baseline characteristics are shown in Table 1. The majority of patients were male and white, with a median 171 
age of 35 years. Recent incarceration was common, and previous TB, IDU, and HCV co-infection were 172 
significantly more common among MDR-TB patients. The median baseline CD4 cell count was 91 173 
(interquartile range [IQR] 31-230) cells/mm3, and only 82 (17%) patients were on ART. 174 
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DST patterns for MDR-TB patients 175 
Among the 105 patients with MDR-TB at baseline, DST results (obtained at any time during TB treatment) 176 
for other drugs ranged from 51-95% for group 1 drugs, 75-78% for group 2/3 drugs, and 49-69% for group 4 177 
drugs (Table 2). The timing of DST testing for individual TB drugs is shown in Table 3a. Overall, 13 (12%) of 178 
MDR-TB patients had XDR-TB, 20 (19%) had pre-XDR, 35 (33%) had MDR, and 37 patients had insufficient 179 
data to determine pre-XDR/XDR-TB status. 180 
Treatment regimen and outcomes 181 
In Fig. 1, TB treatment regimens and outcomes are depicted from baseline through 21 months of follow-up. 182 
WHO recommended regimens were initiated in the majority of individuals with drug-susceptible TB but 183 
maintained well beyond the recommended 6 months. Despite the high population prevalence of MDR-TB, 184 
very few subjects received empiric therapy that provided cover against drug-susceptible and (multi)drug 185 
resistant TB (category 2). High rates of death were observed among MDR-TB patients and those without 186 
DST. Loss to follow-up (from both TB and HIV care) was high, ranging from 8% of MDR-TB patients to 19-187 
20% among patients with pan-susceptible TB or no DST.  188 
TB treatment for MDR-TB patients 189 
Only 8 (8%) of MDR-TB patients initiated an adequate empiric MDR-TB regimen (category 3), which 190 
increased to 35 (44% of patients still under follow-up) after three months. A total of 49 MDR-TB patients 191 
ever received category 3 treatment after a median of 1.2 months (IQR 0.4-2.3), and by 12 months, an 192 
estimated 57.3% (95%CI=41.5-74.1%) had started adequate MDR-TB treatment. Similar results were 193 
obtained when excluding patients with known pre-XDR-TB or XDR-TB (data not shown).  194 
Fluoroquinolones and second-line injectables were uncommon components of initial treatment and, if 195 
used, commonly used without adequate companion drugs (Table 3b/c). By three months, a quarter of 196 
MDR-TB patients still had not initiated a fluoroquinolone or a second-line injectable. Group 4 drugs were 197 
Page 8 of 28
9 
 
variably used, a single patient had received linezolid (introduced late during the course of treatment), and 198 
no patients had received bedaquiline or delamanide. Culture conversion was documented in 45/105 (43%) 199 
of MDR-TB patients and 77/130 (59%) of patients with pan-susceptible TB after a median of 3.0 (IQR 1.8-200 
5.1) and 2.3 (IQR 1.7-4.9, p=0.30) months, respectively. 201 
Activity of TB treatment for MDR-TB patients 202 
Fig. 2a-c illustrates the total number of drugs and the total number of “potentially” active drugs and 203 
“known” active drugs, respectively, in the MDR-TB treatment regimens. While most patients received 4 or 204 
more drugs in their regimen during the first year of treatment, more than 70% received 0, 1 or 2 drugs with 205 
demonstrated activity. A regimen containing 5 or more known active drugs was received by less than 15% 206 
of patients and a regimen containing 5 or more potentially active drugs by less than 40% of patients.  207 
HIV treatment for MDR-TB patients 208 
Despite 77% of MDR-TB patients at the time of their TB diagnosis already having an HIV diagnosis and the 209 
majority being severely immunosuppressed with a median CD4 cell count of 100 cells/mm3, only 13% were 210 
on ART at baseline (Table 1). The proportion on ART among those who remained in care increased to more 211 
than 60% (Figure 3). The majority of those on ART did not have regular HIV-RNA monitoring, and less than 212 
20% of MDR-TB patients were documented to have had an undetectable HIV-RNA (<500 copies/mL) at any 213 
stage during follow up. The Kaplan-Meier estimate of starting ART by eight weeks was only 23%; similar 214 
results were observed for patients with drug-susceptible TB and those with no DST results (data not 215 
shown). 216 
 217 
Discussion      218 
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This study shows suboptimal management of MDR-TB in HIV-positive patients in EE. Despite the high 219 
prevalence of MDR-TB, full DST testing was often restricted and delayed, resulting in prolonged use of 220 
inappropriate or failing regimens that contained few active drugs and suboptimal intensification strategies, 221 
with only half of patients ultimately receiving recommended MDR-TB therapy. In addition, we observed a 222 
low uptake of ART, inadequate viral load monitoring and low rates of HIV-RNA suppression. All of these 223 
factors are likely to have contributed to the mortality rate of nearly 50% at two years. These data point 224 
towards opportunities to improve management of HIV-positive individuals with TB in parts of EE. 225 
The similar characteristics of patients with and without MDR-TB preclude public health strategies based on 226 
risk-stratification of patients and argue for routine DST in all TB patients. Rapid TB diagnostics and DST such 227 
as line-probe assays or cartridge-based molecular tests for Mtb and rifampicin resistance (16) should be 228 
introduced as a priority (25), with routine evaluation of genotypic or phenotypic DST for fluoroquinolones 229 
and second line injectables of all rifampicin-resistant isolates. Thirty-nine percent of those tested for MDR-230 
TB in our cohort had MDR-TB which is consistent with other recent reports from the EE region (8, 26). Of 231 
the patients with MDR-TB, approximately one-third had MDR, one-third had pre-XDR or XDR-TB, and one-232 
third did not have sufficient DST data to assess whether they had (pre-)XDR-TB. We also found common co-233 
resistance to other drugs, as described in another European multicenter study (27). Despite the setting of 234 
high MDR-TB prevalence in EE, empiric therapy rarely provided cover for MDR-TB. This is also problematic 235 
as selection for additional drug-resistance is more likely to occur early on when the bacillary burden is high. 236 
It is worth noting, however, that four in five patients who later were shown to have fully susceptible TB, 237 
initially received adequate RHZ-based treatment, as recently described (28). 238 
In patients with MDR-TB, there were significant delays to initiate treatment for MDR-TB, and many patients 239 
never received adequate MDR-TB treatment as defined by international guidelines (19). The number of 240 
active drugs remained low at all time points; only one-third of patients were treated at some stage with at 241 
least five potentially active drugs, and only one-sixth of patients received regimens with 5 drugs known to 242 
Page 10 of 28
11 
 
have activity against their Mtb isolate. This is of concern as recent studies demonstrate improved outcomes 243 
with optimal MDR-TB regimens (≥5 likely effective drugs) (29-31). Optimal MDR-TB treatment requires 244 
continued, unrestricted access to high quality medications; in a recent survey we documented that this was 245 
not the case in many clinics in EE (32). In agreement with this, linezolid, bedaquiline and delamanid were 246 
generally not used although widespread use in the current context raises significant opportunities for these 247 
drugs to be rapidly lost due to the emergence of resistance.  248 
There is now solid evidence that ART should be initiated shortly after TB diagnosis, especially in patients 249 
with MDR-TB and those with CD4 cell counts below 50 cells/mm3 (33-36). In our study, patients were 250 
severely immunosuppressed, and two-thirds of those who remained under follow-up at three months had 251 
initiated ART. However, less than 20% had documented suppressed viral loads at any time which is well 252 
short of the WHO goal of virological suppression in 90% of patients receiving ART (37). 253 
We documented a mortality rate of nearly 50% within the first two years following initiation of TB 254 
treatment, which is similar to the mortality observed in a retrospective study from our group of HIV-255 
patients with MDR-TB in EE which was conducted in the period 2004-2006 (14). Retrospective African 256 
studies reported mortality rates among HIV-positive patients with MDR-TB of 15-31% (38-40) and a meta-257 
analysis of outcomes found a pooled mortality rate of 38% (41).  The vast majority of deaths in our 258 
retrospective cohort were due to TB (42), which underscores the particular need for high-quality TB 259 
management for people with HIV. Other circumstances may have played a role in determining outcome of 260 
MDR-TB patients in EE. A disintegrated health care system with separated TB and HIV management remains 261 
common (32) and is likely to contribute to poor coordination of care to this often very vulnerable patient 262 
population. In particular, opioid substitution therapy for IDU is severely restricted or even prohibited in 263 
some countries despite documented positive effects on adherence to treatment and health care in general 264 
(43). 265 
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Our observational study has several limitations including the intrinsic risk of selection bias. The participating 266 
clinics were primarily located in major cities and may not be representative of all clinics across EE. DST was 267 
done locally and methods for performing DSTs varied between clinics, and when calculating the number of 268 
active drugs, we counted all drugs as equally effective which is likely to be an over-simplification. A large 269 
number of patients had missing DST results, CD4 cell counts and HIV-RNA measurements precluding a more 270 
robust evaluation of immune-virological outcomes. Nonetheless, the circumstances described reflect the 271 
difficulties for many HIV and TB clinicians working in EE, although substantial regional variability in the 272 
prevalence of MDR-TB and availability of DST, TB and ART drugs, and HIV-RNA measurements exists (12). 273 
Due to limited number of patients with MDR-TB we did not assess intraregional variability.  274 
 275 
Conclusion 276 
In EE, there is an urgent need for access to rapid diagnostics to guide initial TB treatment, to extended DST 277 
to all patients diagnosed with rifamycin-resistant or MDR-TB and to provide better access to second line 278 
drugs to allow the administration of optimally active MDR-TB regimens. Integration of TB and HIV services 279 
can ensure better management and support for people with HIV who frequently have IDU and HCV 280 
coinfection, including rapid initiation of fully suppressive ART.    281 
 282 
Acknowledgements 283 
The TB:HIV Study Group 284 
Eastern Europe 285 
Belarus: Belarusian State Medical University, Department of Infectious Disease: I. Karpov (PI), A. Vassilenko; 286 
Republican Research and Practical Centre for Pulmonology and TB (Minsk): A. Skrahina (PI), D. Klimuk, A. 287 
Page 12 of 28
13 
 
Skrahin, O. Kondratenko and A. Zalutskaya; Gomel State Medical University (Gomel): V. Bondarenko (PI), V. 288 
Mitsura, E. Kozorez, O. Tumash; Gomel Region Centre for Hygiene: O. Suetnov (PI) and D. Paduto.  289 
Estonia: East Viru Central Hospital (Kohtla-Jarve): V. Iljina (PI) and T. Kummik.   290 
Georgia: Infectious Diseases, AIDS and Clinical Immunology Research Center (Tiblisi): N. Bolokadze (PI), K. 291 
Mshvidobadze and N. Lanchava; National Center for Tuberculosis and Lung Diseases of Georgia (Tibilisi): L. 292 
Goginashvili, L. Mikiashvili and N. Bablishvili. 293 
Latvia: Infectology Centre of Latvia (Riga): B. Rozentale (PI), I. Zeltina and I. Janushkevich.  294 
Lithuania: Centre for Communicable Diseases and AIDS (Vilnius): I. Caplinskiene (PI), S. Caplinskas, Z. 295 
Kancauskiene.  296 
Poland:  Wojewodski Szpital Zakanzy/Medical University of Warsaw (Warszawa): R. Podlasin (PI), A. 297 
Wiercinska-Drapalo (PI), M. Thompson and J. Kozlowska; Wojewodski Szpital Specjalistyczny/Medical 298 
University Teaching Hospital (Bialystok): A. Grezesczuk (PI); Jozef Strus Multidisciplinary City Hospital 299 
(Poznan): M. Bura (PI); Wroclaw University School of Medicine (Wroclaw): B. Knysz (PI) and M. Inglot; 300 
Jagiellonian University Medical College (Krakow): A. Garlicki (PI) and J. Loster.  301 
Romania: Dr. Victor Babes Hospital (Bucharest): S. Tetradov (PI) and D. Duiculescu (†).   302 
Russia: Botkin Hospital of Infectious Diseases (St. Petersburg): A. Rakhmanova (PI†), O. Panteleeva, A. 303 
Yakovlev, A. Kozlov, A. Tyukalova and Y. Vlasova; City TB Hospital No. 2 (St. Petersburg): A. Panteleev (PI); 304 
Center for Prevention and Control of AIDS (Veliky, Novgorod): T. Trofimov (PI); Medical University 305 
Povoljskiy Federal Region.  306 
Ukraine: Crimean Republican AIDS Centre (Simferopol): G. Kyselyova (PI).  307 
Western Europe: 308 
Denmark: Rigshospitalet (Cph): AB.  Andersen (PI); Hvidovre University Hospital: K. Thorsteinsson.  309 
Page 13 of 28
14 
 
Belgium: CHU Saint-Pierre (Brussels): MC Payen (PI), K. Kabeya and C. Necsoi. 310 
France: Aquitaine Cohort. Cohort administration: F. Dabis (PI) and M. Bruyand. Participating Centers and 311 
Physicians: Bordeaux University Hospital: P. Morlat; Arcachon Hospital: A. Dupont; Dax Hospital: Y. Gerard; 312 
Bayonne Hospital: F. Bonnal; Libourne Hospital: J. Ceccaldi; Mont-de-Marsan Hospital: S. De Witte; Pau 313 
Hospital: E. Monlun; Périgueux Hospital: P. Lataste; Villeneuve-sur-Lot Hospital: I. Chossat.  314 
Switzerland, Swiss HIV Cohort Study (SHCS, www.shcs.ch): Cohorte administration: M. Sagette and M. 315 
Rickenbach. Participating Centers and Physicians: University Hospital Basel:  L. Elzi and M. Battegay; 316 
University Hospital Bern: H. Furrer (PI); Hopital Cantonal Universitaire, Geneve: D. Sculier and A. Calmy; 317 
Centre Hospitalaire Universitaire Vaudois, Lausanne: M. Cavassini; Hospital of Lugano:  A. Bruno and E. 318 
Bernasconi; Cantonal Hospital St. Gallen: M. Hoffmann and P. Vernazza; University Hospital Zurich: J. Fehr 319 
and Prof. R. Weber.  This study has been co-financed within the framework of the Swiss HIV Cohort Study, 320 
supported by the Swiss National Science Foundation (grant # 148522) and by SHCS project 666. The data 321 
are gathered by the Five Swiss University Hospitals, two Cantonal Hospitals, 15 affiliated hospitals and 36 322 
private physicians).The members of the Swiss HIV Cohort Study are: Aubert V, Battegay M,  Bernasconi E, 323 
Böni J, Bucher HC,  Burton-Jeangros C, Calmy A, Cavassini M, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, 324 
Furrer H (Chairman of the Clinical and Laboratory Committee), Fux CA, Gorgievski M, Günthard H (President 325 
of the SHCS), Haerry D (deputy of "Positive Council"), Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, 326 
Kaiser L, Keiser O, Klimkait T, Kouyos R, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, 327 
Metzner K, Müller N, Nadal D, Nicca D, Pantaleo G, Rauch A (Chairman of the Scientific Board),  Regenass S, 328 
Rickenbach M (Head of Data Center), Rudin C (Chairman of the Mother & Child Substudy), Schöni-Affolter F, 329 
Schmid P, Schüpbach J, Speck R, Tarr P, Telenti A, Trkola A, Vernazza P, Weber R, Yerly S. 330 
United Kingdom: Mortimer Market Centre (London): R. Miller (PI) and N. Vora; St. Mary’s Hospital: G. 331 
Cooke (PI) and S. Mullaney; North Manchester General Hospital: E. Wilkins (PI) and V. George; Sheffield 332 
Teaching Hospitals: P. Collini (PI) and D. Dockrell; King’s College Hospital (London): F. Post (PI), L. Campbell, 333 
Page 14 of 28
15 
 
R. Brum, E. Mabonga and P. Saigal. Queen Elizabeth Hospital: S. Kegg (PI); North Middlesex University 334 
Hospital: J. Ainsworth (PI) and A. Waters. Leicester Royal Infirmary: J. Dhar (PI) and L. Mashonganyika.  335 
Southern Europe: 336 
Italy: IRCCS - Ospedale L. Spallanzani (Rome): E. Girardi (PI), A Rianda, V. Galati, C. Pinnetti and C. Tommasi; 337 
AO San Gerardo (Monza): G. Lapadula (PI); IRCCS AOU San Martino – IST di Genoa (Genova): A. Di Biagio (PI) 338 
and A. Parisini; Clinic of Infectious Diseases, University of Bari (Bari): S. Carbonara (PI), G. Angarano  and M. 339 
Purgatorio; University of Brescia Spedali Civili: A. Matteelli (PI) and A. Apostoli.  340 
Spain: Barcelona Cohort funded by the Spanish HIV/AIDS Research Network. Instituto de Salud Carlos III, 341 
Ministerio de Economía y Competitividad, Madrid (Spain) provided JMM a personal intensification research 342 
grant #INT15/00168 during 2016.: Hospital Clinic of Barcelona: J.M. Miro (PI), C. Manzardo, C. Ligero and J. 343 
Gonzalez; Hospital del Mar: F. Sanchez, H. Knobel, M. Salvadó and J.L. Lopez-Colomes; Mutua de Terrassa: 344 
X. Martínez-Lacasa and E. Cuchí; Hospital Universitari Vall d’Hebrón: V. Falcó, A. Curran, M.T. Tortola, I. 345 
Ocaña and R. Vidal; Hospital Universitari de la Santa Creu i Sant Pau: MA. Sambeat, V. Pomar and P. Coll; 346 
Hospital Universitari de Bellvitge: D. Pozamczer, M. Saumoy and F. Alcaide; Agencia de Salud Pública de 347 
Barcelona: J. Caylà, A. Moreno, J.P. Millet, A. Orcau, L. Fina, L. del Baño, L.L. Roldan. Hospital Universitario 348 
Donostia (San Sebastian): JA. Iribarren (PI) and M. Ibarguren; Hospital Universitario Ramon y Cajal (Madrid): 349 
S. Moreno (PI) and A. González; Hospital Universitario ’Gregorio Maranon’ (Madrid): P. Miralles (PI) and T. 350 
Aldámiz-Echevarría.  351 
Latin America 352 
The CICAL Cohort: Cohorte administration: M. Losso (PI), J. Toibaro and L. Gambardella. Participating 353 
Centers and Physicians: Argentina: Hospital J. M. Ramos Mejía (Buenos Aires): J. Toibaro and L. Moreno 354 
Macias; Hospital Paroissien (BA): E. Warley (PI) and S. Tavella; Hospital Piñero (BA): O. Garcia Messina and 355 
O. Gear; Hospital Nacional Profesor Alejandro Posadas: H. Laplume;  Hospital Rawson (Cordoba): C. Marson 356 
(PI); Hospital San Juan de Dios (La Plata): J. Contarelia and M. Michaan; Hospital General de Agudos 357 
Page 15 of 28
16 
 
Donación F. Santojani: P. Scapellato and D. D Alessandro; Hospital Francisco Javier Muñiz (BA): B. Bartoletti 358 
and D. Palmero; Hospital Jujuy: C. Elias.  Chile: Fundación Arriaran (Santiago): C. Cortes. México: INNcMZS 359 
(México DF): B. Crabtree (PI); Hospital General Regional de Leon- CAPACITS: JL Mosqueda Gomez; Hospital 360 
Civil de Guadalajara: A. Villanueva and LA Gonzalez Hernandez.  361 
 362 
TB:HIV Steering Committee 363 
H. Furrer, E. Girardi, J. A. Caylá, M. H. Losso, J. D. Lundgren, A. Panteleev (co-chair), R. Miller, J.M. Miro, Å. 364 
B. Andersen, S. Tetradov, F. A. Post (co-chair),  A. Skrahin and J. Toibaro. 365 
 366 
Statistical centre 367 
A. Schultze, A. Mocroft. 368 
 369 
Coordinating centre  370 
AM. W. Efsen, M. Mansfeld, B. Aagaard, B. R. Nielsen, A H. Fisher, E.V. Hansen, D. Raben, D. N. Podlekareva, 371 
O. Kirk. 372 
Funding 373 
Funding: This work was supported by EU – 7th Framework (FP7/2007-2013, EuroCoord n 260694) 374 
programme. The funding source had no role in study design, the collection, analysis and interpretation of 375 
data; in the writing of the report; and in the decision to submit the article for publication. 376 
 377 
Disclosure of Potential Conflicts of Interest 378 




RFM reports personal fees from Gilead, ViiV, Merck, and Jannsen outside the submitted work (non-380 
promotional lectures on clinical aspects of HIV infection). JMM reports grants and personal fees from 381 
Abbvie, BMS, Cubist, Genentech, Gilead, Medtronik, MSD, Novartis, and ViiV Healthcare outside the 382 
submitted work. EG reports personal fees from Otsuka Novel products, Angelini, Gilead, Jannsen outside 383 
the reported work. HJF reports grants from Abbvie, Gilead, MSD, BMS, ViiV, all paid to his institution 384 
outside the submitted work. OK reports personal fees and non-financial support from Gilead, personal fees 385 
from ViiV, non-financial support from Bristol Myers-Squibb outside the submitted work. All other authors 386 
report no conclict of interest.  387 
 388 
References 389 
1. World Health Organization. Global Tuberculosis Report 2015. 390 
http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf. Accessed 1 October 2017. 391 
2. Zumla A, Chakaya J, Centis R, D'Ambrosio L, Mwaba P, Bates M, et al. Tuberculosis treatment 392 
and management--an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet 393 
Respir Med. 2015;3(3):220-34. 394 
3. Daley CL, Caminero JA. Management of multidrug resistant tuberculosis. Semin Respir Crit 395 
Care Med. 2013;34(1):44-59. 396 
4. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, et al. Evolution 397 
and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet. 2014;46(3):279-86. 398 
5. Acosta CD, Dadu A, Ramsay A, Dara M. Drug-resistant tuberculosis in Eastern Europe: 399 
challenges and ways forward. Public Health Action. 2014;4(Suppl 2):S3-S12. 400 
6. Balabanova Y, Ignatyeva O, Fiebig L, Riekstina V, Danilovits M, Jaama K, et al. Survival of 401 
patients with multidrug-resistant TB in Eastern Europe: what makes a difference? Thorax. 2016. 402 
7. Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, Hoffner S, et al. Multidrug-403 
resistant tuberculosis in Belarus: the size of the problem and associated risk factors. Bull World Health 404 
Organ. 2013;91(1):36-45. 405 
8. Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, van Gemert W, et al. Alarming 406 
levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J. 2012;39(6):1425-407 
31. 408 
9. UNAIDS. AIDS by the numbers. WORLD AIDS DAY 2015. 409 
http://www.unaids.org/sites/default/files/media_asset/AIDS_by_the_numbers_2015_en.pdf. Accessed 1 410 
October 2017. 411 
10. Yablonskii PK, Vizel AA, Galkin VB, Shulgina MV. Tuberculosis in Russia. Its history and its 412 
status today. Am J Respir Crit Care Med. 2015;191(4):372-6. 413 
11. DeHovitz J, Uuskula A, El-Bassel N. The HIV epidemic in Eastern Europe and Central Asia. Curr 414 
HIV/AIDS Rep. 2014;11(2):168-76. 415 
12. Efsen AM, Schultze A, Post FA, Panteleev A, Furrer H, Miller RF, et al. Major Challenges in 416 
Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and 417 
Latin America. PLoS One. 2015;10(12):e0145380. 418 
13. Late presenters working group in CiE, Mocroft A, Lundgren J, Antinori A, Monforte A, 419 
Brannstrom J, et al. Late presentation for HIV care across Europe: update from the Collaboration of 420 
Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Euro Surveill. 421 
2015;20(47). 422 
Page 17 of 28
18 
 
14. Post FA, Grint D, Werlinrud AM, Panteleev A, Riekstina V, Malashenkov EA, et al. Multi-drug-423 
resistant tuberculosis in HIV positive patients in Eastern Europe. J Infect. 2014;68(3):259-63. 424 
15. Podlekareva DN, Efsen AM, Schultze A, Post FA, Skrahina AM, Panteleev A, et al. 425 
Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international 426 
cohort study. Lancet HIV. 2016;3(3):e120-31. 427 
16. World Health Organization. Guidelines for the programmatic management of drug-resistant 428 
tuberculosis 2011 update. http://apps.who.int/iris/bitstream/10665/44597/1/9789241501583_eng.pdf. 429 
Accessed 1 October 2017. 430 
17. Gunther G, Gomez GB, Lange C, Rupert S, van Leth F, Tbnet. Availability, price and 431 
affordability of anti-tuberculosis drugs in Europe: a TBNET survey. Eur Respir J. 2015;45(4):1081-8. 432 
18. Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho AC, et al. 433 
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a 434 
TBNET consensus statement. Eur Respir J. 2014;44(1):23-63. 435 
19. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis 2016 436 
update. http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf. Accessed 1 October 437 
2017. 438 
20. Conradie F, Diacon A, Everitt D, Mendel C, Niekerk C et al. THE NIX-TB TRIAL OF 439 
PRETOMANID, BEDAQUILINE AND LINEZOLID TO TREAT XDR-TB. Abstract number 80LB. Oral presentation 440 
from Conference on Retroviruses and Opportunistic Infections (CROI), 13-16 February 2017.  441 
21. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, et al. Multidrug resistant 442 
pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis 443 
of 9,153 patients. PLoS Med. 2012;9(8):e1001300. 444 
22. Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, et al. Drug-resistant 445 
tuberculosis: time for visionary political leadership. Lancet Infect Dis. 2013;13(6):529-39. 446 
23. Strobe statement. http://strobe-statement.org/index.php?id=strobe-home. Accessed 1 447 
October 2017.. 448 
24. World Health Organization. Treatment of tuberculosis guidelines fourth edition. 2010. 449 
http://apps.who.int/iris/bitstream/10665/44165/1/9789241547833_eng.pdf?ua=1&ua=1. Accessed 1 450 
October 2017. 451 
25. Xie YL, Chakravorty S, Armstrong DT, Hall SL, Via LE, Song T, et al. Evaluation of a Rapid 452 
Molecular Drug-Susceptibility Test for Tuberculosis. N Engl J Med. 2017;377(11):1043-54. 453 
26. Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, et al. Population-based 454 
resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a 455 
multicountry surveillance project. Lancet Infect Dis. 2016;16(10):1185-92. 456 
27. Gunther G, van Leth F, Altet N, Dedicoat M, Duarte R, Gualano G, et al. Beyond multidrug-457 
resistant tuberculosis in Europe: a TBNET study. Int J Tuberc Lung Dis. 2015;19(12):1524-7. 458 
28. Podlekareva D.N. SA, Panteleev A., Skrahina A.M., Miro J.M., Rakhmanova A., Furrer H., 459 
Miller R.F., Efsen A.M.W., Losso M.H., Toibaro J., Vassilenko A., Girardi E., Lundgren J.D., Mocroft A., Post 460 
F.A., Kirk O., and the TB:HIV study in EuroCoord#. One-year mortality of HIV-positive patients treated for 461 
rifampicin- and isoniazid- susceptible tuberculosis in Eastern Europe, Western Europe and Latin America. 462 
Accepted for publication in AIDS, November 2016. 463 
29. Ahmad Khan F, Gelmanova IY, Franke MF, Atwood S, Zemlyanaya NA, Unakova IA, et al. 464 
Aggressive Regimens Reduce Risk of Recurrence After Successful Treatment of MDR-TB. Clin Infect Dis. 465 
2016. 466 
30. Franke MF, Appleton SC, Mitnick CD, Furin JJ, Bayona J, Chalco K, et al. Aggressive regimens 467 
for multidrug-resistant tuberculosis reduce recurrence. Clin Infect Dis. 2013;56(6):770-6. 468 
31. Velasquez GE, Becerra MC, Gelmanova IY, Pasechnikov AD, Yedilbayev A, Shin SS, et al. 469 
Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure 470 
and death. Clin Infect Dis. 2014;59(1):9-15. 471 
Page 18 of 28
19 
 
32. Mansfeld M, Skrahina A, Shepherd L, Schultze A, Panteleev AM, Miller RF, et al. Major 472 
differences in organization and availability of health care and medicines for HIV/TB coinfected patients 473 
across Europe. HIV Med. 2015;16(9):544-52. 474 
33. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, et al. Timing of 475 
initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362(8):697-706. 476 
34. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, et al. Earlier versus later 477 
start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16):1471-81. 478 
35. Group ISS, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of 479 
Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795-807. 480 
36. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, et al. Timing of 481 
antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011;365(16):1482-91. 482 
37. UNAIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic 2014. 483 
http://www.unaids.org/en/resources/documents/2017/90-90-90. Accessed 1 October 2017. 484 
38. Satti H, McLaughlin MM, Hedt-Gauthier B, Atwood SS, Omotayo DB, Ntlamelle L, et al. 485 
Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for 486 
HIV co-infected patients in Lesotho. PLoS One. 2012;7(10):e46943. 487 
39. Shin SS, Modongo C, Boyd R, Caiphus C, Kuate L, Kgwaadira B, et al. High Treatment Success 488 
Rates among HIV-infected Multidrug-resistant Tuberculosis Patients after Expansion of Antiretroviral 489 
Therapy in Botswana, 2006-2013. J Acquir Immune Defic Syndr. 2016. 490 
40. Umanah T, Ncayiyana J, Padanilam X, Nyasulu PS. Treatment outcomes in multidrug resistant 491 
tuberculosis-human immunodeficiency virus Co-infected patients on anti-retroviral therapy at Sizwe 492 
Tropical Disease Hospital Johannesburg, South Africa. BMC Infect Dis. 2015;15:478. 493 
41. Isaakidis P, Casas EC, Das M, Tseretopoulou X, Ntzani EE, Ford N. Treatment outcomes for 494 
HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. Int J Tuberc Lung 495 
Dis. 2015;19(8):969-78. 496 
42. Podlekareva DN, Panteleev AM, Grint D, Post FA, Miro JM, Bruyand M, et al. Short- and long-497 
term mortality and causes of death in HIV/tuberculosis patients in Europe. Eur Respir J. 2014;43(1):166-77. 498 
43. Morozova O, Dvoryak S, Altice FL. Methadone treatment improves tuberculosis treatment 499 




Page 19 of 28
20 
 
Figure 1: TB treatment and outcomes over time among 105 patients with MDR-TB (left), 183 with no DST (middle) and 130 patients with 504 
susceptible TB (right) from time of start of TB treatment. 505 
 506 
R = Rifampicin 507 
H = Isoniazid 508 
Z = Pyrazinamide 509 
E = Ethambutol 510 
S = Streptomycin 511 
FQ = Fluoroquinolone 512 
2L-inj = Second-line injectables 513 
LTFU = Loss to follow-up 514 
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Figure 2a-c: Number of total TB drugs (a), potentially active* (b), and known active** (c) TB drugs at each time point for 105 MDR-TB 517 
patients under follow-up. 518 
*Potentially active: Assuming susceptibility where DST for a specific drug was missing. 519 
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Figure 3. Antiretroviral (ART) status over time for MDR-TB patients (N=105)* 526 
 527 
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Table 1. Baseline characteristics of the included individuals (N=485) 531 
  Total MDR-TB* All other groups P
7 
  N (%) N (%) N (%)  
Total  485 105 380  
Gender Male 374 (77) 84 (80) 290 (76) 0.43 
Ethnicity
1 
White 442 (94) 98 (96) 344 (94) 0.42 
Previous TB
2 
Yes 64 (13) 24 (23) 40 (11) <0.01 
TB risk factors Prison 91 (19) 22 (21) 69 (18) 0.52 
 Alcohol 128 (26) 30 (29) 98 (26) 0.57 
 Family 41 (8) 12 (11) 29 (8) 0.22 
 Travel 0 0 0 N/A 
Injection drug use (ever) Yes 327 (67) 80 (76) 247 (65) 0.03 
OST (ever) Yes 6 (1) 0 (0) 6 (2) 0.32 
Hepatitis C
3 
Yes 254 (52) 59 (56) 195 (51) 0.03 
TB type Pulmonary 176 (36) 45 (43) 131 (34) 0.27 
 Extra pulmonary 24 (5) 4 (4) 20 (5)  
 Disseminated 285 (59) 56 (53) 229 (60)  
HIV+ >3 months before TB diagnosis Yes 354 (73) 81 (77) 273 (72) 0.28 
ART
7 
Yes 82 (17) 14 (13) 68 (18) 0.27 
  Median (IQR)    
Age Year 35 (31-40) 35 (31-40) 35 (31-40) 0.75 
Weight
4
 Kg 60 (53-68) 63 (55-68) 59 (53-68) 0.29 
CD4 cell count
5 
(cells/mm3) 91 (31-230) 100 (32-267) 89 (31-220) 0.59 
HIV-RNA
6 
Log10 copies/ml 5.25 (4.40-5.75) 5.42 (4.46-5.91) 5.22 (4.35-5.70) 0.13 
1. 9 individuals had missing data on previous TB. 532 
2. 17 individuals had missing data on ethnicity. 533 
3. 148 individuals had missing data on hepatitis C. 534 
4. 300 individuals had missing weight at baseline. 535 
5. 87 individuals had missing baseline CD4. 536 
6. 211 individuals had missing baseline HIV-RNA. 537 
7. P-values compare the characteristics between individuals with MDR-TB and all other individuals in included in the study. The chi-squared test, fischer’s exact test, or Mann-Whitney u 538 
test was used as appropriate. 539 
OST = Opioid substitution therapy. 540 
ART = antiretroviral therapy.541 
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Table 2. Results from drug susceptibility test performed at any time point in follow-up among all patients with 542 
MDR-TB (N=105) 543 
Drug  N (%) with data N (% of those tested) with resistance 
Group 1    
Pyrazinamide  54 (51) 30 (56) 
Ethambutol  100 (95) 72 (72) 
Streptomycin  75 (71) 72 (96) 
Group 2    
Fluoroquinolones  79 (75) 22 (28) 
Group 3    
Second-line injectables  82 (78) 35 (43) 
Group 4    
Ethionamide/Prothionamide  72 (69) 23 (32) 
Cycloserine/Terizidone  51 (49) 8 (16) 
Para-Aminosalicylic Acid (PAS)  61 (58) 10 (16) 
 544 
 545 
  546 
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Table 3. DST performance and TB drug use among patients with MDR-TB (N=105) 547 
                                             3a: N (%) of patients who had DST performed per drug up to the indicated time point among those under follow-up at given time point 
 N R H Z E FQ 2L-inj PT/ET CS/TZ PAS BDQ DLM LNZ 
0 105 49 (47) 49 (47) 27 (26) 46 (44) 35 (33) 37 (35) 32 (30) 16 (15) 24 (23) 0 0 0 
1 month  88 88 (100) 88 (100) 47 (53) 82 (93) 63 (72) 66 (75)  57 (65) 40 (45) 47 (53) 0 0 0 
2 months 79 79 (100) 79 (100) 44 (56) 74 (94) 58 (73) 64 (81) 54 (68) 40 (51) 45 (57) 0 0 0 
3 months 72 72 (100) 72 (100) 40 (56) 68 (94) 54 (75) 61 (85) 51 (71) 37 (51) 41 (57) 0 0 0 
7 months 56 56 (100) 56 (100) 42 (57) 53 (95) 43 (77) 47 (84) 40 (71) 30 (54) 33 (59) 0 0 0 
13 months 44 44 (100) 44 (100) 25 (57) 42 (95) 35 (80) 37 (84) 30 (70) 22 (50) 26 (59) 0 0 0 
21 months 31 31 (100) 31 (100) 16 (52) 29 (94) 23 (74) 25 (81) 23 (74) 16 (52) 22 (71) 0 0 0 
              
 3b: N (%) of patients under follow-up who received selected anti-TB medications at the indicated time point 
 N R H Z E FQ 2L-inj PT/ET CS/TZ PAS BDQ DLM LNZ 
0 105 86 (82) 89 (85) 90 (86) 84 (80) 16 (15) 23 (22) 14 (13) 10 (10) 4 (4) 0 0 0 
1 month 88 57 (65) 59 (67) 76 (86) 68 (77) 32 (36) 38 (43) 31 (35) 23 (26) 17 (19) 0 0 0 
2 months 79 39 (49) 37 (47) 66 (84) 53 (67) 43 (54) 46 (58) 40 (51) 30 (38) 29 (34) 0 0 0 
3 months 72 23 (32) 23 (32) 55 (76) 37 (51) 51 (71) 48 (67) 49 (68) 39 (54) 33 (46) 0 0 0 
7 months 56 6 (11) 5 (9) 42 (75) 21 (38) 50 (89) 39 (70) 47 (84) 37 (66) 31 (55) 0 0 1 (2) 
13 months 44 5 (11) 4 (9) 34 (77) 14 (32) 39 (89) 15 (34) 33 (75) 27 (61) 20 (45) 0 0 0 
21 months 31 2 (6) 1 (3) 20 (65) 7 (23) 25 (81) 8 (26) 19 (61) 22 (71) 15 (48) 0 0 0 
              
 3c: N (%) of patients under follow-up who had ever received selected TB medications at the indicated time point  
 N R H Z E FQ 2L-inj PT/ET CS/TZ PAS BDQ DLM LNZ 
0 105 86 (82) 89 (85) 90 (86) 84 (80) 16 (15) 23 (22) 14 (13) 10 (10) 4 (4) 0 0 0 
1 month 88 76 (86) 75 (85) 81 (92) 76 (86) 33 (38) 40 (45) 32 (36)       23 (26) 17 (19) 0 0 0 
2 months 79 68 (86) 66 (84) 72 (91) 68 (86) 45 (60) 49 (62) 41 (52) 31 (39) 29 (37) 0 0 0 
3 months 72 62 (86) 61 (85) 66 (92) 61 (85) 54 (75) 55 (76) 51 (71) 40 (56) 36 (50) 0 0 0 
7 months 56 47 (84) 47 (84) 53 (95) 51 (91) 51 (91) 49 (88) 48 (86) 40 (71) 33 (59) 0 0 1 (2) 
13 months 44 39 (89) 39 (89) 42 (95) 42 (95) 40 (91) 38 (86) 37 (84) 31 (70) 24 (55) 0 0 0 
21 months 31 27 (87) 27 (87) 29 (94) 30 (97) 29 (94) 28 (90) 26 (84) 23 (74) 20 (65) 0 0 0 
DST = Drug Susceptibility Test 548 
R = Rifampicin 549 
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H = Isoniazid 550 
Z = Pyrazinamide 551 
E = Ethambutol 552 
FQ = Fluoroquinolone 553 
2L-inj = Second-line injectables 554 
PT/ET = Prothionamide/Ethionamide 555 
CS/TZ = Cycloserine/Terizidone 556 
PAS = Para-aminosalicylic acid 557 
BDQ = Bedaquiline 558 
DLM = Delamanide 559 
LNZ = Linezolid  560 
 561 
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